The one vial that is tested and trusted.
Leading Advances in Cytology

For more than 20 years, healthcare providers have trusted ThinPrep® more than any other brand. The ThinPrep Pap test has shown to be significantly more effective than conventional Pap testing* and become the preferred choice in liquid-based cytology today, with **more than 650 million** ThinPrep Pap tests performed so far.¹

* The ThinPrep 2000 System is significantly more effective than conventional Pap smear for detection of low-grade squamous intraepithelial (LSIL) and severe lesions in a variety of patient populations.²
A Wealth of Knowledge in a Single Vial

**Trust the Track Record**

- **Significantly more effective** than conventional Pap smear for the detection of LSIL and more severe lesions.2*
- **59.7% higher HSIL detection** than conventional Pap testing.2*
- **The only Pap test FDA-approved** for improved ability to detect glandular disease compared to conventional Pap.7
- **The only collection medium** approved for use with all FDA-approved and all CE-marked HPV tests.§

**The ThinPrep® Pap Test Collection Process Provides:**

**Patient Comfort**
Only one sample needed for cytology and molecular testing.

**Efficiency**
Scalable levels of automation to optimize lab efficiency.

**Chain-of-Custody Verification**
Closed-system processing supports strong chain-of-custody.

**Overcoming Conventional Limitations**

**Conventional Pap Smear**
- Only a fraction of collected sample is used in slide preparation.3
- Sample smearing factors often produce **poor cell quality**.3
- Slide **may fail** to accurately represent sample and not reflect patient’s actual condition.3
- Cells on slide may overlap or be **obscured** by blood, mucus or other material, making visualization of cells difficult.4

**ThinPrep® Pap Test**
- Nearly all of collected sample is retained in the ThinPrep vial.3
- Immediate fixation **maintains cell quality**.3
- Slides **accurately** represent sample for increased opportunity to detect abnormality.3
- Cells on slide are **cleared** of obscuring elements and distributed evenly for ease of visualization.2
- Produces multiple **representative and reproducible** samples.2

---

* The ThinPrep 2000 System is significantly more effective than conventional Pap smear for detection of low-grade squamous intraepithelial (LSIL) and severe lesions in a variety of patient populations.

§ Aptima® HPV assay, Aptima® HPV 16/18/45 Genotype assay, Cervista® HPV HR Test, Cervista® HPV 16/18 Test, Roche cobas HPV Test and Hybrid Capture 2 HPV DNA test.
## Versatile Application

<table>
<thead>
<tr>
<th>Multifaceted Functionality</th>
<th>ThinPrep®</th>
<th>SUREPATH®</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-Approved and CE-marked:</td>
<td>1996</td>
<td>1999</td>
</tr>
<tr>
<td>Improved Specimen Adequacy</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Improved HSIL Detection</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Glandular Disease Labeling Detection</td>
<td>✓*</td>
<td>—</td>
</tr>
<tr>
<td>FDA-Approved for Every Adjunctive HPV Test</td>
<td>✓</td>
<td>—†</td>
</tr>
<tr>
<td>Adjunctive CT/NG Approval / Clearance</td>
<td>For All FDA-Approved CT/NG Tests</td>
<td>Only Cleared on the BD ProbeTec QCT and GC Assays with the Viper System</td>
</tr>
<tr>
<td>Adjunctive Trichomonas vaginalis Clearance</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td>Adjunctive Mycoplasma genitalium Clearance</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td>Shelf Life: Aptima® HPV assays‡</td>
<td>30 days†</td>
<td>7 days‡</td>
</tr>
<tr>
<td>Digene® HC2 assay‡</td>
<td>90 days†</td>
<td>28 days‡</td>
</tr>
<tr>
<td>cobas® HPV assay‡</td>
<td>180 days†</td>
<td>14 days‡</td>
</tr>
</tbody>
</table>

* The ThinPrep Pap test is the only Pap test with FDA-approved labeling supported by multiple peer-reviewed publications reporting increased glandular disease detection.
† Surepath is only approved for ASCUS Reflex and co-testing with Roche cobas.
‡ At room temperature.

### Sample Integrity Preservation

**ThinPrep® Pap Test**
- Collection device rinsed in ThinPrep vial.³
- Virtually 100% of sample preserved.³
- Full contents of vial preserved for use in slide preparation.³

**SurePath® Pap Test**
- Brush head deposited in vial.¹⁰
- Sample transferred from vial to tube.¹⁰
- Up to 33% of epithelial cells lost.¹⁰
- Up to 7% of abnormal cells discarded in this process.¹⁰

20 mL Total Sample Volume
4 mL Pre-Aliquot Removal Volume: Extra volume for ancillary testing.²

Just 10 mL Total Sample Volume
Only 0.5 mL Pre-Aliquot Removal Volume: Ancillary testing limited.
Increased Disease Detection

HSIL and LSIL Categorization

The College of American Pathologists (CAP) reported increased HSIL and LSIL categorization rates in labs that used the ThinPrep Pap test in 679 U.S. laboratories.11

Addressing a Dangerous Threat

The ThinPrep Pap test is the only pap test with FDA-approved labeling that is supported by multiple peer-reviewed publications reporting increased detection of adenocarcinoma (glandular disease).12-17

Sensitivity for Cervical Adenocarcinoma12

"The ThinPrep Pap test ... produces more reliable results in detecting abnormalities of glandular cells."18
The Imager clinical trial results showed a statistically significant increase in ASCUS+ sensitivity of 6.4% [95% CI: 2.6-10.0], a statistically significant increase in HSIL+ specificity of 0.2% [95% CI: 0.06-0.4], and a reduction in false negative fraction of 39% (based on ASCUS+ sensitivity). The unsatisfactory rate was not evaluated for statistical significance, but a decrease was observed.

**Increased sensitivity** and specificity over manually reviewed ThinPrep Pap test slides.*

**Improved standardization** at each stage of sample processing and staining.

**39% Reduced false-negative results.**

**Targeted areas:** Imager identifies largest and darkest nuclei for review.

“Biopsy follow-up showed that the significant increase in HSIL diagnoses in the imager group was due to the detection of true disease rather than false positive cytologic diagnoses.”

* The Imager clinical trial results showed a statistically significant increase in ASCUS+ sensitivity of 6.4% [95% CI: 2.6-10.0], a statistically significant increase in HSIL+ specificity of 0.2% [95% CI: 0.06-0.4], and a reduction in false negative fraction of 39% (based on ASCUS+ sensitivity). The unsatisfactory rate was not evaluated for statistical significance, but a decrease was observed.
Imaging Raises the Bar in Pap Testing Results

Imaging elevates workflow in your lab and provides greater LSIL and HSIL categorization versus non-imaged slides.

A Step Ahead with Imaging

Slides screened with the ThinPrep Imaging system showed greater LSIL and HSIL categorization versus non-imaged slides.

Independent Studies Show Increased LSIL and HSIL Cytology Categorization vs Manual ThinPrep Pap Test
The Complete Solution for Cervical Health Screening.